JDQ443

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Patients With Advanced Solid TumorsNSCLC

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 2

192

Eloxatin

Teva

Phase 2

93

Camptosar

Pfizer

Phase 2

44

Tecentriq

Roche

Phase 2

45

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

156

Lazcluze

Johnson & Johnson

Phase 2

17

Erbitux

IImclone

Phase 2

98

Tuoyi

CCoherus Oncology, Inc.

Phase 2

99

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

610

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

KRAS G12C Mutant Solid Tumors2 trials

KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Terminated·Novartis·Preclinical·NCT05358249·74 enrolled

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting·Novartis·Preclinical·NCT04699188·344 enrolled

Brain Metastases1 trial

JDQ443 for KRAS G12C NSCLC Brain Metastases

Withdrawn·MMaastricht University Medical Center·Phase 2·NCT05999357

Hepatic Impairment1 trial

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Completed·Novartis·Phase 1·NCT05329623·33 enrolled

NSCLC1 trial

Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05714891·4 enrolled

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation1 trial

KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Active, not recruiting·Novartis·Phase 2·NCT05445843·95 enrolled

1 more indication

Non-Small Cell Lung Cancer1 trial

A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Active, not recruiting·Novartis·Phase 3·NCT05132075·95 enrolled

Details

Drug Info

Related News